Bone Short Long Term Debt vs Current Deferred Revenue Analysis

BBLGW Stock

USD 60.50 0.00 0.00%

Bone Biologics financial indicator trend analysis is way more than just evaluating Bone Biologics Corp prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Bone Biologics Corp is a good investment. Please check the relationship between Bone Biologics Short Long Term Debt and its Current Deferred Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bone Biologics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

Short Long Term Debt vs Current Deferred Revenue

Short Long Term Debt vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Bone Biologics Corp Short Long Term Debt account and Current Deferred Revenue. At this time, the significance of the direction appears to have strong relationship.

The correlation between Bone Biologics' Short Long Term Debt and Current Deferred Revenue is 0.75. Overlapping area represents the amount of variation of Short Long Term Debt that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Bone Biologics Corp, assuming nothing else is changed. The correlation between historical values of Bone Biologics' Short Long Term Debt and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Long Term Debt of Bone Biologics Corp are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Short Long Term Debt i.e., Bone Biologics' Short Long Term Debt and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

0.75

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Short Long Term Debt

The total of a company's short-term and long-term borrowings.

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most indicators from Bone Biologics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bone Biologics Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bone Biologics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

At this time, Bone Biologics' Enterprise Value Over EBITDA is fairly stable compared to the past year. Enterprise Value Multiple is likely to climb to 0.20 in 2024, whereas Selling General Administrative is likely to drop slightly above 2 M in 2024.

	2022	2023	2024 (projected)
Tax Provision	3.2K	3.7K	2.1K
Interest Expense	2.2M	2.0M	1.5M

Tax Provision Interest Expense

Bone Biologics fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Net Debt	Cash	Cash And Short Term Investments	Total Current Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Retained Earnings	Other Stockholder Equity	Total Liab	Common Stock	Short Long Term Debt Total	Other Current Assets	Short Term Debt	Accounts Payable	Net Receivables	Non Current Liabilities Total	Inventory	Current Deferred Revenue	Long Term Debt	Net Invested Capital	Net Working Capital	Short Long Term Debt	Capital Stock
Common Stock Shares Outstanding		-0.39	-0.21	-0.36	-0.42	-0.39	-0.49	-0.34	0.24	0.67	-0.63	-0.51	-0.56	-0.74	-0.39	-0.37	-0.2	-0.61	-0.08	0.7	-0.52	-0.44	-0.23	0.03	-0.37	0.21
Total Assets	-0.39		-0.65	0.99	0.76	1.0	0.65	-0.11	0.62	-0.45	0.59	-0.25	-0.07	0.55	0.67	-0.31	-0.27	0.35	-0.57	-0.33	0.38	0.44	0.9	0.61	0.49	-0.58
Net Debt	-0.21	-0.65		-0.68	-0.34	-0.66	-0.18	0.56	-0.99	-0.02	-0.12	0.89	0.73	0.08	-0.43	0.82	0.34	0.21	0.81	-0.21	0.01	-0.15	-0.8	-0.78	-0.28	0.7
Cash	-0.36	0.99	-0.68		0.78	0.99	0.66	-0.12	0.64	-0.47	0.62	-0.29	-0.11	0.55	0.7	-0.29	-0.29	0.4	-0.57	-0.34	0.43	0.48	0.94	0.61	0.51	-0.59
Cash And Short Term Investments	-0.42	0.76	-0.34	0.78		0.76	0.71	0.39	0.28	-0.57	0.66	0.04	0.05	0.66	0.92	0.06	0.19	0.55	-0.16	-0.44	0.55	0.59	0.64	0.08	0.64	-0.38
Total Current Assets	-0.39	1.0	-0.66	0.99	0.76		0.65	-0.11	0.62	-0.45	0.59	-0.25	-0.07	0.55	0.67	-0.31	-0.27	0.35	-0.57	-0.33	0.38	0.44	0.9	0.61	0.49	-0.58
Other Current Liab	-0.49	0.65	-0.18	0.66	0.71	0.65		0.21	0.08	-0.52	0.6	0.22	0.41	0.57	0.6	0.03	0.02	0.59	-0.02	-0.71	0.34	0.31	0.56	0.2	0.34	-0.17
Total Current Liabilities	-0.34	-0.11	0.56	-0.12	0.39	-0.11	0.21		-0.6	-0.32	0.24	0.68	0.46	0.38	0.28	0.62	0.52	0.42	0.31	-0.36	0.3	0.31	-0.31	-0.84	0.07	0.3
Total Stockholder Equity	0.24	0.62	-0.99	0.64	0.28	0.62	0.08	-0.6		0.07	0.06	-0.92	-0.77	-0.13	0.37	-0.83	-0.36	-0.27	-0.82	0.29	-0.05	0.12	0.77	0.78	0.25	-0.7
Retained Earnings	0.67	-0.45	-0.02	-0.47	-0.57	-0.45	-0.52	-0.32	0.07		-0.96	-0.35	-0.33	-0.93	-0.71	-0.37	-0.3	-0.87	0.05	0.88	-0.91	-0.83	-0.46	-0.02	-0.76	0.53
Other Stockholder Equity	-0.63	0.59	-0.12	0.62	0.66	0.59	0.6	0.24	0.06	-0.96		0.23	0.26	0.93	0.74	0.28	0.22	0.86	-0.14	-0.84	0.91	0.86	0.61	0.14	0.79	-0.54
Total Liab	-0.51	-0.25	0.89	-0.29	0.04	-0.25	0.22	0.68	-0.92	-0.35	0.23		0.91	0.45	-0.09	0.86	0.32	0.52	0.72	-0.54	0.27	0.09	-0.49	-0.65	-0.04	0.53
Common Stock	-0.56	-0.07	0.73	-0.11	0.05	-0.07	0.41	0.46	-0.77	-0.33	0.26	0.91		0.43	-0.12	0.7	0.18	0.53	0.6	-0.61	0.21	-0.08	-0.3	-0.38	-0.17	0.48
Short Long Term Debt Total	-0.74	0.55	0.08	0.55	0.66	0.55	0.57	0.38	-0.13	-0.93	0.93	0.45	0.43		0.69	0.42	0.29	0.82	0.03	-0.82	0.84	0.81	0.44	0.01	0.76	-0.42
Other Current Assets	-0.39	0.67	-0.43	0.7	0.92	0.67	0.6	0.28	0.37	-0.71	0.74	-0.09	-0.12	0.69		-0.05	0.33	0.55	-0.25	-0.5	0.65	0.72	0.66	0.15	0.8	-0.65
Short Term Debt	-0.37	-0.31	0.82	-0.29	0.06	-0.31	0.03	0.62	-0.83	-0.37	0.28	0.86	0.7	0.42	-0.05		0.21	0.63	0.69	-0.43	0.49	0.24	-0.42	-0.68	0.06	0.52
Accounts Payable	-0.2	-0.27	0.34	-0.29	0.19	-0.27	0.02	0.52	-0.36	-0.3	0.22	0.32	0.18	0.29	0.33	0.21		0.12	0.33	-0.26	0.22	0.23	-0.33	-0.53	0.3	-0.13
Net Receivables	-0.61	0.35	0.21	0.4	0.55	0.35	0.59	0.42	-0.27	-0.87	0.86	0.52	0.53	0.82	0.55	0.63	0.12		0.17	-0.88	0.89	0.68	0.35	-0.14	0.53	-0.14
Non Current Liabilities Total	-0.08	-0.57	0.81	-0.57	-0.16	-0.57	-0.02	0.31	-0.82	0.05	-0.14	0.72	0.6	0.03	-0.25	0.69	0.33	0.17		-0.14	-0.03	-0.21	-0.69	-0.55	-0.1	0.69
Inventory	0.7	-0.33	-0.21	-0.34	-0.44	-0.33	-0.71	-0.36	0.29	0.88	-0.84	-0.54	-0.61	-0.82	-0.5	-0.43	-0.26	-0.88	-0.14		-0.73	-0.59	-0.31	0.06	-0.5	0.25
Current Deferred Revenue	-0.52	0.38	0.01	0.43	0.55	0.38	0.34	0.3	-0.05	-0.91	0.91	0.27	0.21	0.84	0.65	0.49	0.22	0.89	-0.03	-0.73		0.86	0.44	-0.05	0.75	-0.42
Long Term Debt	-0.44	0.44	-0.15	0.48	0.59	0.44	0.31	0.31	0.12	-0.83	0.86	0.09	-0.08	0.81	0.72	0.24	0.23	0.68	-0.21	-0.59	0.86		0.51	-0.01	0.89	-0.57
Net Invested Capital	-0.23	0.9	-0.8	0.94	0.64	0.9	0.56	-0.31	0.77	-0.46	0.61	-0.49	-0.3	0.44	0.66	-0.42	-0.33	0.35	-0.69	-0.31	0.44	0.51		0.71	0.54	-0.71
Net Working Capital	0.03	0.61	-0.78	0.61	0.08	0.61	0.2	-0.84	0.78	-0.02	0.14	-0.65	-0.38	0.01	0.15	-0.68	-0.53	-0.14	-0.55	0.06	-0.05	-0.01	0.71		0.2	-0.58
Short Long Term Debt	-0.37	0.49	-0.28	0.51	0.64	0.49	0.34	0.07	0.25	-0.76	0.79	-0.04	-0.17	0.76	0.8	0.06	0.3	0.53	-0.1	-0.5	0.75	0.89	0.54	0.2		-0.66
Capital Stock	0.21	-0.58	0.7	-0.59	-0.38	-0.58	-0.17	0.3	-0.7	0.53	-0.54	0.53	0.48	-0.42	-0.65	0.52	-0.13	-0.14	0.69	0.25	-0.42	-0.57	-0.71	-0.58	-0.66

Click cells to compare fundamentals

Bone Biologics Account Relationship Matchups

Bone Biologics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	12.2K	12.1K	18.9K	47.6K	263.1K	250.0K
Total Assets	30.8K	0.0	6.7M	8.5M	3.7M	2.3M
Net Debt	11.3M	11.7M	(6.7M)	(7.5M)	(3.0M)	(2.9M)
Cash	24.1K	0.0	6.7M	7.5M	3.0M	2.0M
Cash And Short Term Investments	955.4K	24.1K	6.7M	7.5M	3.0M	2.1M
Liabilities And Stockholders Equity	30.8K	13.7M	6.7M	8.5M	3.7M	3.5M
Total Current Assets	30.8K	0.0	6.7M	8.5M	3.7M	2.3M
Other Current Liab	513.7K	535.6K	1.5M	2.5M	470.7K	447.2K
Total Current Liabilities	578.4K	13.7M	99.9K	2.5M	831.4K	789.8K
Total Stockholder Equity	(11.9M)	(13.7M)	6.6M	5.9M	2.9M	3.1M
Retained Earnings	(67.0M)	(68.9M)	(70.5M)	(72.0M)	(80.9M)	(76.9M)
Total Liab	11.9M	13.7M	99.9K	2.5M	831.4K	789.8K
Short Long Term Debt Total	8.2M	9M	11.3M	11.7M	13.5M	8.3M
Other Current Assets	105.2K	85.3K	6.7K	956.9K	711.2K	746.8K
Accounts Payable	42.9K	465.4K	99.9K	888.46	360.7K	202.9K
Non Current Liabilities Total	11.3M	12.2M	99.9K	888.46	799.61	759.63
Net Invested Capital	(547.6K)	(2.0M)	6.6M	5.9M	2.9M	2.1M
Net Working Capital	(547.6K)	(13.7M)	6.6M	5.9M	2.9M	3.1M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

S	SentinelOne
MSFT	Microsoft
MSFT	Microsoft

Additional Tools for Bone Stock Analysis

When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Bone Short Long Term Debt vs Current Deferred Revenue Analysis

Short Long Term Debt vs Current Deferred Revenue

Short Long Term Debt vs Current Deferred Revenue Correlation Analysis

Correlation Coefficient

Short Long Term Debt

Current Deferred Revenue

Bone Biologics fundamental ratios Correlations

Bone Biologics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Bone Biologics fundamental ratios Accounts

Also Currently Popular

Additional Tools for Bone Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Cash	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Cash
Net Invested Capital	+ 0.94	Cash
Short Long Term Debt Total	+ 0.93	Other Stockholder Equity
Other Current Assets	+ 0.92	Cash And Short Term Investments

Total Stockholder Equity	- 0.99	Net Debt
Other Stockholder Equity	- 0.96	Retained Earnings
Short Long Term Debt Total	- 0.93	Retained Earnings
Total Liab	- 0.92	Total Stockholder Equity
Current Deferred Revenue	- 0.91	Retained Earnings
Inventory	- 0.88	Net Receivables